Category: INFORMATION

28 January – Data Protection Day: privacy, health and trust

European Data Protection Day, observed every year on 28 January, was established by the Council of Europe and is linked to Convention 108, the first legally binding international instrument on the protection of personal data. The day serves as a reminder that the right to privacy is a fundamental human right — especially in a time when personal information is increasingly collected, stored and processed digitally.

Personal data are not merely technical entries in databases and systems. They are fragments of people’s lives. They include health information, personal experiences, vulnerable moments and deeply private aspects of identity. When individuals share such information, they do so with the expectation that it will be handled with care, confidentiality and respect.

For organisations such as Kapa3, which work closely with patients and people in vulnerable situations, data protection goes far beyond legal compliance. It is a matter of dignity and trust. Health data — including information related to both physical and mental health — belong to the most sensitive categories of personal data. Inadequate protection or misuse can lead to stigma, discrimination and a profound sense of insecurity.

Within the European Union, the General Data Protection Regulation (GDPR) provides a common framework to ensure that individuals retain control over their personal information. Rights such as informed consent, access to data and the ability to request deletion are not administrative formalities. They are essential safeguards that protect human integrity, particularly in the context of healthcare and social support.

According to the World Health Organization (WHO), confidentiality and ethical governance of health data are fundamental to the provision of safe and high-quality care. Trust between patients and healthcare or support organisations is strengthened when personal information is managed transparently, responsibly and within clearly defined limits.

European Data Protection Day is not only an occasion to reflect on legal obligations or technical safeguards. It is an opportunity to consider how we approach privacy as a core element of respectful and ethical care. Protecting personal data is ultimately not about technology — it is about protecting the people behind the data and the trust that underpins every meaningful human relationship.

Sources:

Text/adaptation: Ifiyenia Anastasiou for Kapa3

Biomarkers Open New Paths in Cancer Treatment in Greece

Good news for cancer patients in Greece — access to personalized treatments is now becoming a reality.

A recent decision by the Ministry of Health (ΦΕΚ Β’ 5627/20-10-2025, Απόφαση Δ3(α) 41081/2025) approves and reimburses a wider range of biomarker tests, marking an important step forward for modern oncology care.

Read the Government Gazette here

But what are biomarkers?
They are special indicators detected through molecular tests that help doctors understand the unique characteristics of each patient’s cancer. In simple terms, biomarkers act like a “compass,” guiding doctors to choose the most effective and safest treatment for every individual.

Until now, only a few biomarkers were covered by the public health system — for example, molecular signatures that determine whether a woman with early-stage breast cancer needs chemotherapy (approved in 2018), or BRCA1/2 gene tests that reveal inherited risk for breast and ovarian cancer.

The new decision significantly expands this list, adding additional biomarkers for 39 indications. This allows oncologists to tailor treatments to the specific profile of each patient’s tumor, bringing Greece closer to international standards of personalized medicine.

KAPA3, which consistently supports patient education and empowerment, welcomes this development as a vital step toward more human-centred, targeted care.

This progress brings hope, better quality of life, and greater trust in the healthcare system. It is only the beginning, but it lays strong foundations for a future where every patient has access to the right treatment, at the right time.

Learn about patient rights via KAPA3’s extensive library here

Learn more about cancer biomarkers here

Text/Adaptation: Ifiyenia Anastasiou for Kapa3

Free and Reduced Transportation for People with Disabilities and Large Families – What Changes in 2025

The Greek state is implementing significant changes regarding transportation for people with disabilities and large families in 2025. The new regulations simplify procedures, expand rights, and make public transport more accessible for all eligible individuals.

People with Disabilities (PwD)
Who is eligible:
Eligible individuals include people with disabilities with a disability rate of 67% or higher, or those receiving disability benefits from OPEKA. Totally blind individuals and holders of a digital Disability Card marked with levels II or III are exempt from income limits.

What changes:

  • Residency criteria are removed.
  • The right to free or reduced transportation now extends to one accompanying person, if needed.
  • Using the Disability Card for OASA, OSETH, KTEL, and Thessaloniki Metro is now simple with electronic or personalized card validation, without additional documents.

Practical use:

  • Free travel on OASA, OSETH, urban KTEL, and the municipalities of Kos and Rhodes.
  • 50% discount on intercity KTEL routes.
  • Thessaloniki Metro requires topping up the ThessCard with zero fare.
  • Accompanying persons can travel without separate validation when accompanying the eligible individual.

Large Families
Who is eligible:
Eligible individuals are large families and their members, according to existing legislation protecting large families.

What changes:

  • Travel with OASA, OSETH, and KTEL becomes more flexible.
  • Free or discounted tickets are supported depending on the policy of each transport service.

Practical use:

  • Simple procedure for issuing travel passes through Citizens’ Service Centers (KEP) and relevant regional authorities.
  • Tickets are valid for urban and intercity transport services.

These new regulations simplify the daily lives of people with disabilities and large families, reduce bureaucracy, and make access to all public transport easier.

See the Official Government Gazette (FEK) here

Read more about citizens’ rights here

Read more about the Disability Card here 

Text/Adaptation: Ifiyenia Anastasiou for Kapa3

 

Gut Microbiota: A Hidden Ally in Cancer Treatment

Our gut is home to trillions of microorganisms, collectively called the gut microbiota, which play a crucial role in digestion, immunity, and overall health. Excitingly, research is revealing that these tiny residents can also influence the effectiveness of cancer treatments—from immunotherapy to chemotherapy and beyond. Understanding this connection opens new possibilities for more personalized and effective cancer care.

Boosting Immunotherapy through Gut Microbes

Innovative therapies like CAR-T cell therapy, immune checkpoint inhibitors (ICIs), oncolytic viruses (OVs), and CpG-oligonucleotide immunotherapy have transformed cancer treatment in recent years. Studies show that the composition of gut microbiota can affect how well patients respond to these therapies.

For instance, certain bacteria—such as Ruminococcus, Faecalibacterium, and Akkermansia—are linked to better CAR-T outcomes, while broad-spectrum antibiotics may reduce therapy effectiveness. Similarly, gut microbes can enhance responses to ICIs by stimulating immune cells that attack tumors. OVs, which work by killing cancer cells and activating the immune system, also benefit from a healthy gut microbiota. Even CpG-based therapies are more effective when gut microbes activate immune pathways.

In short, a balanced gut microbiota can help “turn cold tumors into hot tumors,” making them more responsive to modern immunotherapies.

Gut Microbes and Traditional Treatments

Gut microbiota also affects chemotherapy and radiotherapy. Some microbes can influence drug metabolism, improving efficacy or reducing side effects. For example, bacteria like Enterococcus hirae and Barnesiella intestinihominis enhance the response to cyclophosphamide, a common chemotherapy drug, by activating immune cells.

On the other hand, disruptions in gut microbiota—often caused by antibiotics or radiation—can increase treatment toxicity, leading to issues like intestinal inflammation or mucositis. Promising strategies like fecal microbiota transplantation (FMT) and certain probiotics have shown potential to restore gut balance, reduce side effects, and improve overall outcomes.

Complementary Approaches: TCM and Probiotics

Traditional medicine can also benefit from gut microbes. Traditional Chinese Medicine (TCM) compounds, when processed by gut bacteria, can transform into more potent anti-cancer agents. Certain TCM herbs and formulas can also promote beneficial bacteria while suppressing harmful ones.

Similarly, probiotics, prebiotics, and synbiotics—foods or supplements that nourish or contain helpful bacteria—can support cancer treatment by strengthening gut immunity, reducing inflammation, and enhancing drug effectiveness. For example, in combination with chemotherapy or immunotherapy, synbiotics have been shown to reduce treatment-related side effects while boosting therapeutic benefits.

Emerging Strategies: Engineering the Microbiota

Beyond diet and probiotics, scientists are developing targeted microbiota interventions to fight cancer more precisely. These include:

  • Engineered microbes, designed to deliver anti-cancer agents directly to tumors.
  • Phage therapy, using viruses that selectively kill harmful bacteria.
  • Nanomedicine and OMVs (outer membrane vesicles), which can deliver drugs or immune-stimulating molecules to tumors while sparing healthy microbes.

These cutting-edge approaches are still under study, but they demonstrate the incredible potential of harnessing gut microbes to improve therapy effectiveness and reduce toxicity.

Looking Ahead: Precision Medicine and Microbiota

The future of cancer treatment may increasingly involve personalized microbiota strategies. By analyzing an individual’s gut bacteria and metabolites, clinicians could tailor therapies to maximize efficacy and minimize side effects. Combining microbiota profiling with multi-omics analysis, AI, and big data could allow doctors to predict treatment response and guide interventions in a way that was unimaginable just a decade ago.

While challenges remain—including differences in individual microbiotas, safety considerations, and regulatory hurdles—the potential is enormous. Gut microbiota represents a promising frontier in precision oncology, offering hope for more effective, safer, and individualized cancer care.

Read the full article here

Text/Adaptation: Ifiyenia Anastasiou for Kapa3

Continuing the Journey: Holistic Body and Mind Care with Kapa3 and the University of the Peloponnese

After the first round of meetings held in April (see the related article here), focusing on Nutritional Guidance and Experiential Psychological Support, Kapa3 and the University of the Peloponnese continue their collaboration with a new series of experiential workshops dedicated to the holistic care of body and mind.

The meetings are open to people living with cancer, caregivers, and healthcare professionals — to anyone seeking a space for genuine communication, understanding, and empowerment.

In this new cycle, mental health and nutrition are approached as two sides of the same care.

In the mental health sessions, participants learn to recognize and manage challenging emotions such as anxiety or fear, strengthen their resilience, and cultivate a deeper connection with themselves and others.

At the same time, the nutrition sessions explore how balanced and mindful eating can support the body, enhance energy and mood, and become an act of self-care and self-respect. Food is not only a necessity but also a way to show love — to the body, the soul, and to life itself.

The meetings are held online and are based on dialogue, experiential learning, and the sharing of personal experiences. Everyone participates at their own pace, in a warm environment of acceptance and trust.

To express your interest: Registration Form for the Support Group for People with Cancer

Text/adaptation: Ifiyenia for Kapa3

World Health Summit Side Meeting: Building Healthier Digital Futures with Information Integrity

One Week to Go: World Health Summit 2025!

From October 12–14, global leaders, researchers, and innovators will gather in Berlin for the World Health Summit 2025, tackling some of the most pressing global health challenges. This year, the focus is on Health Information Integrity, emphasizing the importance of reliable, accurate, and accessible health information in an era dominated by search engines, social media, and AI tools.

Highlights of the Summit include:

  • October 13 – The Future of Quality Health Information: A workshop presenting the Nature Medicine Commission’s work on ensuring quality health information for all, and exploring ways to measure its impact and economic value. Learn more

  • October 14 – Building Healthier Digital Futures with Information Integrity: A side event on how transparent governance and resilient information systems can protect communities from misinformation and disinformation amplified by algorithms and viral content. Learn more

The Summit brings together experts and decision-makers worldwide to explore solutions for improving health information quality and promoting evidence-based decision-making.

 

The new OECD report (2025) highlights Greece’s challenges and priorities in cancer

The new OECD report (2025) highlights Greece’s challenges and priorities in cancer, comparing them with other European countries.

Key points:

  • Increased incidence: Greece records ~67,000 new cancer diagnoses and ~36,000 deaths annually (2022 data). By 2050, cases are expected to increase by 36%.
  • Risk factors: Smoking, obesity, poor diet, air pollution, low HPV vaccination coverage.
  • Early diagnosis: There are programs for breast, cervical, and colorectal cancer, but they are not yet sufficiently developed or sustainable beyond 2025.
  • Inequalities in care: Staff shortages, geographical inequalities, high out-of-pocket costs, difficulties in access for vulnerable groups.
  • Survivors & caregivers: There is no organized strategy for the quality of life of survivors, while caregivers are overburdened. The “right to be forgotten” does not yet apply in Greece.
  • Data & policy: Until recently, there was no national cancer registry. Greece does not yet have a comprehensive National Cancer Plan, unlike many other European countries.

Conclusion:
Greece is called upon to:

– strengthen prevention and population-based screening,

– reduce inequalities in access,

– support survivors and caregivers,

– and develop a holistic national cancer plan with clear targets and evaluation.

The report clearly shows that the country needs greater investment, better organization, and integration of actions into European planning.

See the report in detail here  22087cfa-en (1)

The main points are given in the file below by the Kapa3 team. OOSA 2025 REPORT

Digital transformation: Health systems’ investment priorities

Health systems around the world are facing a host of challenges, including rising costs, clinical-workforce shortages, aging populations requiring more care (for example, to treat chronic conditions), and increasing competition from nontraditional players.1 At the same time, consumers are expecting new capabilities (such as digital scheduling and telemedicine) and better experiences from health systems across their end-to-end care journeys.2 In response, health systems are increasing their focus on digital and AI transformation to meet consumer demands, address workforce challenges, reduce costs, and enhance the overall quality of care.3 However, despite acknowledging the importance of these efforts to future sustainability, many health system executives say their organizations are still not investing enough.

AI, traditional machine learning, and deep learning are projected to result in net savings of up to $360 billion in healthcare spending.

AI, traditional machine learning, and deep learning are projected to result in net savings of $200 billion to $360 billion in healthcare spending.4 But are health systems investing to capture these opportunities? We recently surveyed 200 global health system executives about their digital investment priorities and progress.5 Seventy-five percent of respondents reported their organizations place a high priority on digital and analytics transformation but lack sufficient resources or planning in this area.

Increasing prioritization

In line with other industries, the majority (nearly 90 percent) of health system executives surveyed, in both technical roles (such as chief information officer or chief technology officer) and nontechnical roles (for example, CEO or CFO), reported that a digital and AI transformation is a high or top priority for their organization. At the same time, 75 percent of respondents reported their organizations are not yet able to deliver on that priority because they have not sufficiently planned or allocated the necessary resources.


Health system digital investment priority areas and anticipated impact

For health system executives, current investment priorities do not always align with areas they believe could have the most impact. There is alignment in some areas, including virtual health and digital front doors, where about 70 percent of respondents expect the highest impact.1 In other areas, such as AI, 88 percent of respondents reported a high potential impact,2 yet about 20 percent of respondents do not plan to invest in the next two years. The absence of investment in a robust, modern data and analytics platform could delay value creation in areas that depend on these capabilities—such as efforts to close gaps in care, improve timely access for referrals, and optimize operating room throughput.

Major headwinds and slow progress

Given the current macroeconomic climate and increasing cost pressures on health systems, most respondents identified budget constraints as a key obstacle to investing at scale across all digital and AI categories of interest (51 percent of respondents ranked this obstacle among the top three). For example, a health system that is building a digital front door may lack the resources to simultaneously invest in the latest generative AI (gen AI) capabilities.

Respondents called out challenges with legacy systems as the second-greatest concern (after budget constraints). Core tech modernization is key to delivering on the digital promise,1 but health systems have typically relied on a smaller set of monolithic systems that have become a challenge to untangle.

Additional highly ranked challenges include data quality (33 percent), tech talent and recruiting (30 percent), and readiness to adopt and scale new technology (34 percent).

Satisfaction with digital investment

Most executives of health systems that have invested in digital priorities (72 percent) reported satisfaction across all investment areas. Among the comparatively fewer respondents who reported investing in robotics and advanced analytics, satisfaction was even higher, at 82 percent and 81 percent, respectively. Given that investments result in a high level of satisfaction and that 75 percent of executives reported they are not yet able to deliver on their digital transformation ambitions (as noted above), health systems may be facing a failure to scale their digital programs.

What health systems can do and how they can learn from other industries

The goal of digital and AI transformation is to fundamentally rewire how an organization operates, building capabilities to drive tangible business value (such as patient acquisition and experience, clinical outcomes, operational efficiency, and workforce experience and retention) through continuous innovation. Delivering digital value for health systems requires investment and new ways of working.

Building partnerships. Scale is crucial to value creation. But the definition of at-scale systems has changed in the past few years; today, it takes more than $13 billion to be a top 20 system by revenue, and many have reached their current position through inorganic growth.6 Partnerships (joint ventures and alliances) may offer a promising avenue to access new capabilities, increase speed to market, and achieve capital, scale, and operational efficiencies.7

Moving beyond off-the-shelf solutions. History shows that deploying technology—such as electronic health records (EHRs)—on top of broken processes and clinical workflows does not lead to value. Realizing value from healthcare technology will require a reimagination (and standardization) of clinical workflows and care models across organizations. For example, optimizing workflows to enable more appropriate delegation, with technical enablement, could yield a potential 15 to 30 percent net time savings over a 12-hour shift. This could help close the nursing workforce gap by up to 300,000 inpatient nurses.8

Using the cloud for modernization. Health systems are increasingly building cloud-based data environments with defined data products to increase data availability and quality. Health systems can also use cloud-hosted, end-user-focused platforms (such as patient or clinician apps) that integrate multiple other applications and experiences to simplify stakeholders’ interactions with the system.

Operating differently. Operating differently entails fundamental changes in structure (flatter, empowered, cross-functional teams), talent (new skill sets and fully dedicated teams), ways of working (outcome orientation, agile funding, and managing products, not projects), and technology (modular architecture, cloud-based data systems, and reduced reliance on the monolithic EHR). With these changes, some health systems have begun to see real value within six months. Building a digital culture helps the transformation succeed over time.9

Cautiously embracing gen AI. Gen AI has the potential to affect everything from continuity of care and clinical operations to contracting and corporate functions. Health system executives and patients have concerns about the risks of AI, particularly in relation to patient care and privacy. Managing these risks entails placing business-minded legal and risk-management teams alongside AI and data science teams.10 Organizations could also implement a well-informed risk-prioritization strategy.

Digital and AI investments provide health systems with opportunities to address the many challenges they face. Successful health systems will invest in areas with the greatest potential impact while removing barriers—for example, by upgrading legacy infrastructure. Health systems that make successful investments in digital and analytics capabilities could see substantial benefits and position themselves to benefit from the $200 billion to $360 billion opportunity.11

ABOUT THE AUTHOR(S)
Jack Eastburn is a partner in McKinsey’s Southern California office; Jen Fowkes is a partner in the Washington, DC, office; and Karl Kellner is a senior partner in the New York office. Brad Swanson is a consultant in the Denver office.

The authors wish to thank David Bueno, Camilo Gutierrez, Dae-Hee Lee, Audrey Manicor, Lois Schonberger, and Tim Zoph for their contributions to this article.

Πηγή: mckinsey.com
find more :https://eefam.gr/digital-transformation-health-systems-investment-priorities/

A Different Chemotherapy Approach for Ovarian Cancer

OVARIAN CANCER that spreads to the lining of the abdominal cavity, called the peritoneum, is difficult to treat. Patients with this advanced cancer typically undergo debulking, also called cytoreductive surgery, a lengthy procedure in which surgeons aim to remove all cancer from the abdominal cavity and affected organs, including the ovaries and fallopian tubes as well as the bladder, colon and other parts of the gastrointestinal tract. In recent years, researchers have looked at the efficacy of using hyperthermic intraperitoneal chemotherapy (HIPEC), which is heated chemotherapy delivered directly to the peritoneum, to destroy remaining cancer cells immediately after debulking surgery.

Scientists in Belgium and the Netherlands published long-term data from OVHIPEC-1, a randomized phase III trial to evaluate adding HIPEC to interval cytoreductive surgery for ovarian cancer, in the October 2023 Lancet Oncology. (In interval surgery, chemotherapy is given to shrink the cancer prior to surgery.) The study enrolled 245 women with stage III epithelial ovarian cancer whose cancer showed no signs of progression after upfront chemotherapy. Researchers randomly assigned women to have debulking surgery alone, or surgery plus HIPEC using the chemotherapy drug cisplatin. After 10 years, median overall survival for the surgery-plus-HIPEC group was 44.9 months versus 33.3 months for the surgery group. Median progression-free survival was 14.3 months and 10.7 months, respectively. The rates of adverse events were similar—25% with surgery alone versus 27% with surgery plus HIPEC—and the most common events were abdominal pain, infection and slowed bowel function.

These results are in line with the researchers’ five-year analysis, published in the New England Journal of Medicine in 2018. In that analysis, 6.6% of patients in the surgery group had survived without progression at five years, compared with 12.3% in the surgery-plus-HIPEC group. At 10 years, 6.6% of the people who received surgery were alive with no progression versus 10.1% in the surgery-plus-HIPEC group. While surgery plus HIPEC did not result in better cure rates, the authors note that it significantly prolonged the time cancer was controlled. “The most important finding is that the benefit for patients with stage III ovarian carcinoma when interval cytoreductive surgery is combined with HIPEC remains present after a 10-year follow up,” says Willemien van Driel, lead author and a gynecologic oncologist at the Netherlands Cancer Institute in Amsterdam, who notes that patients in both arms of the study received similar treatment after subsequent recurrences.

Van Driel says that there is still variation in the use of HIPEC along with cytoreductive surgery. European guidelines published in October 2023 note that HIPEC with cytoreductive surgery should not be considered a standard of care. In the U.S., National Comprehensive Cancer Network guidelines state that HIPEC can be considered for patients with stage III epithelial ovarian cancer.

Van Driel and her colleagues are now enrolling patients in the OVHIPEC-2 trial, which will study the effect of adding HIPEC in women with stage III ovarian cancer undergoing primary surgery, which is surgery done upfront prior to chemotherapy. Other trials are evaluating HIPEC use for recurrent ovarian cancer. She notes there are several unanswered questions, including optimal dosing and temperature for HIPEC and the impact of including other drugs, such as PARP inhibitors, with this approach, since many of these drugs were not standard of care at the time of the trial.

HIPEC may be a valid choice for patients who are generally healthy and open to a longer procedure and hospital stay. Although the length of surgery plus HIPEC varies, HIPEC generally adds 90 minutes or more to debulking surgery, which itself takes several hours. Also, patients typically require a longer hospital stay for recovery, possibly with intravenous or tube feedings while the digestive system recovers. 

Find more :

A Different Chemotherapy Approach for Ovarian Cancer

How to Find the Right Oncologist for You

After a cancer diagnosis, it’s one of the most important decisions you’ll make.

After a career as a golf professional in southeastern New Mexico, Doug Lyle, 76, decided he had somewhere better to be than on the course: spending time with his new grandchild. Then this summer, just as he was settling into retirement, he learned he had prostate cancer.

“When you’re first diagnosed, you immediately go to the internet, and you can be overwhelmed in short order,” he said. “The more you read about it, the more complicated it gets.”

One of the first and most important choices he had to make was who his oncologist would be. Many of the two million patients diagnosed with cancer in the United States each year get the news from a primary care doctor. Those patients might accept a referral to an oncologist without question. But research suggests that it’s worth considering the choice closely: It can shape the care you receive, your satisfaction with the treatment and your chances of survival.

Not everyone has a choice of oncologists. There are fewer providers in rural areas, and patients must travel farther to reach them. Insurers may only cover certain clinicians and hospitals. And patients from certain populations have less access to oncologists for a range of reasons, which may affect the care they receive. For example, research suggests that Black and Hispanic women with breast cancer are more likely than white women to experience delays in starting radiotherapy. And Black men with prostate cancer are less likely than white men to receive treatment that’s intended to cure their condition, even when they’re at similar stages of disease.

No matter your circumstances, you should feel empowered to have a say in who treats your cancer.

Ideally, experts said, you’d be able to easily compare doctors’ levels of experience and the outcomes of patients they’ve treated with your same diagnosis. But such apples-to-apples comparisons are not always easy to make. But “right now, there are no publicly available data to help a patient with cancer say, ‘Oh, this is where I want to go,’” said Dr. Nancy Keating, a physician and professor of health care policy and medicine at Harvard Medical School. (And even if there were, apples-to-apples comparisons are not always easy to make, since patient populations vary from one doctor to the next).

Still, there are some accreditations to look for. The National Cancer Institute has given a special designation to 72 cancer centers, which must show they treat patients in accordance with the latest evidence and also conduct research into new therapies. The American College of Surgeons Commission on Cancer has accredited over 1,500 programs that meet certain standards. And the American Society of Clinical Oncology has several certification programs, including a list of 300 practices recognized for their quality and safety.

There are resources to help you search for oncologists, too, including a U.S. News & World Report directory that lets you sort by location, patient reviews and accepted forms of insurance. The consumer research firm Castle Connolly also has a database of doctors who are nominated by their peers and then evaluated for their qualifications, interpersonal skills and more.

Look for an oncologist who frequently treats patients with diagnoses similar to yours. Research has long shown that when doctors perform certain procedures more often, their patients have better outcomes. One study found that patients of surgeons who removed more than 25 lung cancers a year spent less time in the hospital, had a lower risk of infection and were more likely to survive three years without recurrence of disease.

Dr. Timothy Pawlik, the chair of the surgery department at Ohio State University Wexner Medical Center, said he only treats a handful of cancers. “You want someone with depth, not breadth,” Dr. Pawlik said. That way, he explained, “the patient may have a rare cancer, but it’s not rare to that doctor.”

Additionally, everyone else on the care team including the anesthesiologists and nurses, will also be familiar with your particular cancer and treatment.

Your primary care provider may be able to find someone specializing in your diagnosis. Some physicians’ websites will identify sub-specialties, and you can also ask for guidance from patient advocacy groups focused on your type of cancer. When you reach out to a doctor, don’t be shy about asking how many patients with similar cancers they treat per year.

Mr. Lyle hesitated to get a second opinion for fear of offending the first doctor he’d seen. But he ultimately chose to do so, a step many experts recommend. “Medicine is an art, and there are sometimes differences of opinion,” said Karen Knudsen, the chief executive of the American Cancer Society. Weighing those differences can help you make a more informed choice.

If a second physician agrees with your original treatment plan, it can give you more confidence in the approach. Research suggests a second opinion can also lead to clinically meaningful changes in treatment. One 2023 study of 120 cancer patients found that a for a third of patients, a second opinion led to treatment changes that yielded better outcomes. Many had received evidence-based care from their first doctor but decided after a second opinion to scale back treatments that might have been unnecessary and had harmful side effects.

Mr. Lyle said that during his first conversation with a physician, he didn’t know enough to ask the right questions about his diagnosis and newer treatment options. “The fine points, you’re not aware of yet. So you almost need a rehearsal,” he said. (For help with what to ask during an appointment, the National Comprehensive Cancer Network has detailed information about care for many cancers.)

When it is clinically appropriate, some cancer centers now offer second opinions through telehealth. You can call to see if it’s possible to submit your medical records and get a remote consultation.

Find more: